Tag Archives: drug discovery

Episentum presents at K4DD meeting, Berlin, October 16-18 2017

Posted on by

Episentum will present a poster at the K4DD meeting “Binding kinetics: Time is of the essence” in Berlin, October 16-18 2017. K4DD is an Innovative Medicines Initiative (IMI) program on Kinetics in Drug Discovery. The title of our poster is “Kinetic Analysis of Small-Molecule Binding with Label-Enhanced SPR”.

Looking forward to getting and update on binding kinetics, and to presenting the potential of LE-SPR in this area. For any information on LE-SPR prior to the meeting, or to book a one-to-one meeting, please contact us at info@episentum.com.

 

Presentation at Drug Discovery 2017 Meeting, Liverpool, UK, October 3-4 2017

Posted on by

Episentum will give an oral presentation and exhibit a poster at the Drug Discovery 2017 Meeting, Liverpool, UK, 3-4 October 2017. The title of both contributions is “Label-Enhanced SPR for Improved Surface Plasmon Resonance Analysis of Small Molecules and Biomolecules”.

Looking forward to meeting you in Liverpool! For any information on LE-SPR prior to the meeting, or to book a one-to-one meeting, please contact us at info@episentum.com.

 

Episentum presents at the NovAlix conference Biophysics in Drug Discovery, Strasbourg, France, 6-9 June 2017

Posted on by

Episentum will present a poster on Label-Enhanced SPR at the NovAlix conference Biophysics in Drug Discovery, Strasbourg, France, 6-9 June 2017. We will display the enhanced sensitivity in small molecule analysis, as well as the enhanced specificity and the dual-colour capabilities in protein analysis.

We’re looking forward to meeting with lots of SPR scientists and other biophysicists, including old and new customers. For any information on LE-SPR prior to the meeting, or to book a one-to-one meeting, please contact us at info@episentum.com.

 

Episentum presents at the Advances in Drug Discovery meeting, Cambridge, UK, 6-7 March 2017

Posted on by

Episentum will present a poster at the Advances in Drug Discovery meeting, Cambridge, UK, 6-7 March 2017. The poster will demonstrate how Label-Enhanced SPR can improve the surface plasmon resonance analysis of small molecules as well as larger biomolecules.

We’re looking forward to meeting with lots of SPR users, including old and new customers. For any information on LE-SPR prior to the meeting, or to book a one-to-one meeting, please contact us at info@episentum.com.

 

Meet Episentec at the Drug Discovery ’15 meeting in Telford, UK, 2-3 September 2015

Posted on by

Take the opportunity to meet with Episentec at the ELRIG Drug Discovery ’15 conference in Telford, UK, 2-3 September 2015. We will present a poster showing how Label-Enhanced SPR improves both the detectability and the specificity in Surface Plasmon Resonance analysis of antibodies and proteins as well as small molecules and fragments.

We will also spend a few days extra in the UK, so if you’re interested in Label-Enhanced SPR and if you’re site is not too far from Telford, please contact us and we’ll arrange a meeting!

Please contact us at sales@episentum.com for any enquiries.

Meet Episentec at Fragments 2015 in Cambridge, UK, 22-24 March 2015

Posted on by

We will participate and present a poster on Label-Enhanced SPR at the 5th RSC-BMCS Fragment-based Drug Discovery Meeting in Cambridge, UK, 22-24 March 2015.

We will also spend 25-26 March in the Cambridge area, so if you’re interested in Label-Enhanced SPR and if you’re site is not too far from Cambridge, please contact us and we’ll arrange a meeting!

Please contact us at info@episentum.com for any enquiries.

New Application Note 021 on fragment kinetics

Posted on by

Our new Application Note 021 demonstrates how label-enhanced SPR expands the measurable kinetic space for fragments and small molecules into previously intractable regions. This provides new unique insights into lead optimization of small molecules and a novel understanding of how the dynamics of interactions involving weakly binding and/or low molecular weight compounds relate to protein function.

Please check out our Application Notes page for more info or order the new document directly from sales@episentec.com.

 

Research agreement with AstraZeneca / Press release

Posted on by

Episentec (Solna, Sweden) and AstraZeneca (Mölndal, Sweden) have signed a research collaboration agreement regarding the development and implementation of improved methodology for early screening of potential new drug molecules. The research project, aimed at an undisclosed drug target protein, will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the terms of the agreement, AstraZeneca will supply target protein and small molecules for screening, while Episentec will develop and implement new SPR-based screening methodologies. The goal of the project is to develop cost-efficient screening methods with higher sensitivity, higher specificity, and higher throughput than what is possible using today’s state-of-the-art technologies.

Anders Hanning, CEO of Episentec, comments: “We are very happy to get this opportunity to cooperate with AstraZeneca. We really believe that our Label-Enhanced SPR technology has the potential to take today’s SPR-based screening methods to a new level of performance.”

Stefan Geschwindner, Principal Scientist at AstraZeneca, adds: “Entering this collaboration with Episentec will bring us in a position to significantly expand the current application areas of SPR-based drug screening. Having found an experienced partner in that area makes us feel confident in achieving the goals of this collaboration, for the benefit of enabling unprecedented screening approaches as well as unlocking difficult target classes in the near future.”

For further information please contact:

Anders Hanning, CEO, Episentec anders.hanning@episentec.com +46 70 225 99 96

Stefan Geschwindner, Principal Scientist, Discovery Sciences, AstraZeneca R&D Mölndal stefan.geschwindner@astrazeneca.com +46 31 776 2197

About SPR-based drug screening: SPR (Surface Plasmon Resonance) is an optical biosensor method that is commonly used in the screening of potential new drug molecules. SPR is used to detect which molecules that bind to and interact with a specific disease target, usually a protein. SPR drug screening was pioneered by the Swedish company Biacore™, now part of GE Healthcare.

About Episentec: Episentec is a Swedish biotech company established in 2010 by scientists with a comprehensive experience in the development and application of biosensors. The aim of the company is to develop add-on tools that boost the performance of optical biosensor instruments. Episentec’s proprietary concept “Label-Enhanced SPR” substantially improves the performance of SPR-based biosensor instruments and expands their breadth of application. The company markets the Episentec™ range of dye reagents and EpiGrammer™ software for data evaluation, and also offers services for dye labelling of biomolecules and biosensor method development. For more information please visit: www.episentec.com

About AstraZeneca: AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Drug Design & Medicinal Chemistry Conference, Berlin, 8-9 May 2014

Posted on by

We’re giving an oral presentation and presenting a poster on “Competition-based screening and characterization with Label-Enhanced SPR” at the Drug Design & Medicinal Chemistry Conference in Berlin, 8-9 May 2014. Check here for the full conference programme! Please don’t hesitate to contact us at the conference to discuss how we can help improve your SPR screens!

You are also welcome to contact us at info@episentec.com to book a meeting in advance.

Presenting B2 Dye Labels in Barcelona

Posted on by

We will participate in the Discovery Chemistry Congress in Barcelona, 18-19 February, and present a poster called “Competition-based screening and characterization with Label-Enhanced SPR”. The poster shows how the sensitivity of a Biacore™ instrument can be boosted 100-fold using our new B2 Series dye labels. Please stop by the poster for more information!

We have also published a new Application Note 018 describing highly sensitive kinetic analysis of small molecules on Biacore 2000 using the B2 Series dyes. Please don’t hesitate to contact us at sales@episentec.com for a copy of the Application Note, or for a Product Data Sheet or a Price List of our product range!